Benefit of Drug-eluting Coronary Stents in Reducing In-stent Restenosis

2004 ◽  
Vol 1 (1) ◽  
pp. 88-90
Author(s):  
David R Holmes Jr
Keyword(s):  
Coronary Stents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents

2008 ◽  
Vol 34 (1) ◽  
pp. 62-67 ◽  
Author(s):  
M. Kitoga ◽  
A. Pasquet ◽  
V. Preumont ◽  
J. Kefer ◽  
M.-P. Hermans ◽  
...  
Keyword(s):  
Coronary Stents ◽  
Diabetic Patients ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis

Stent fracture and restenosis after placement of a drug-eluting device in the vertebral artery origin and treatment with the stent-in-stent technique

2007 ◽  
Vol 106 (5) ◽  
pp. 907-911 ◽  
Author(s):  
Seong-Rim Kim ◽  
Min-Woo Baik ◽  
Seung-Hoon Yoo ◽  
Ik-Seong Park ◽  
Sang-Don Kim ◽  
...  
Keyword(s):  
Vertebral Artery ◽  
Stent Placement ◽  
Coronary Stents ◽  
Drug Eluting Stent ◽  
Stent Fracture ◽  
Stent Restenosis ◽  
Stent Strut ◽  
Drug Eluting ◽  
In Stent Restenosis

✓ The authors report two cases of stent fracture and restenosis after placement of a drug-eluting device in the vertebral artery (VA) origin, and describe management of restenosis with the stent-in-stent technique. Two women, one 62 and the other 67 years of age, underwent stent placement in the VA origin to treat symptomatic and angiographically significant stenosis in this vessel. Sirolimus-eluting coronary stents (Cypher) were used in both cases. Four months after placement of the devices, the symptoms recurred. Follow-up angiography performed 5 months after insertion of the devices revealed a transverse stent fracture with separation of the fragments and severe in-stent restenosis in both cases. The restenoses were treated with reinsertion of coronary stents (Cypher and Jostent FlexMaster) by using the stent-in-stent technique. After stent reinsertion, the patients exhibited relief of symptoms. This paper is the first report of fracture in a drug-eluting stent and restenosis after stent placement in the VA origin. Restenosis caused by such a fracture can be managed successfully by performing the stent-in-stent maneuver. The physical properties of metallic devices, stent strut geometry, and anatomical peculiarities of the subclavian artery may be associated with stent fractures. Earlier follow-up angiography studies (within 6 months) are warranted.

Drug-eluting Balloons in Coronary Artery Disease – Current and Future Perspectives

2012 ◽  
Vol 8 (1) ◽  
pp. 56 ◽  
Author(s):  
Anouar Belkacemi ◽  
Pierfrancesco Agostoni ◽  
Michiel Voskuil ◽  
Pieter Doevendans ◽  
Pieter Stella ◽  
...  
Keyword(s):  
Small Vessel Disease ◽  
Percutaneous Treatment ◽  
Added Value ◽  
High Concentration ◽  
Diffuse Disease ◽  
Stent Restenosis ◽  
Alternative Treatment Option ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Percutaneous treatment of complex coronary lesions, such as small-vessel disease, diabetes and long diffuse disease, remain hampered by suboptimal results, even with the use of drug-eluting stents (DES). The paclitaxel drug-eluting balloon (DEB) is an interesting emerging device that optimises clinical outcomes in these specific lesions. The DEB may become a viable alternative treatment option for the inhibition of coronary restenosis and subsequent revascularisation, as it allows local release of a high-concentration antirestenotic drug, paclitaxel, into the coronary vessel without using a metal scaffold or durable polymers. Several studies have already shown promising and consistent results in the treatment of in-stent restenosis. The DEB has demonstrated its added value compared with certain DES. Inspired by these results, an increasing number of studies have been started in different coronary lesion subsets to explore the value of the DEB in a broader range of lesions. It will be interesting to see whether the DEB will find more indications beyond in-stent restenosis treatment. Moreover, will all DEBs offer the same added value, or will there be differences in efficacy among the DEBs produced by the various manufacturers? As was the case in the development of DES, now the puzzle pieces have to be put together for DEB.

scholarly journals TCTAP A-030 Drug Coated Balloon Versus Drug-eluting Stent for In-stent Restenosis After Drug-eluting Stent Implantation: A Meta-analysis

2021 ◽  
Vol 77 (14) ◽  
pp. S19
Author(s):  
Hendy Bhaskara Perdana Putra ◽  
Quri Meihaerani Savitri ◽  
Wally Wahyu Mukhammad ◽  
Atiyatum Billah ◽  
Alan Dharmasaputra ◽  
...  
Keyword(s):  
Stent Implantation ◽  
Meta Analysis ◽  
Drug Eluting Stent ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Coated Balloon ◽  
In Stent Restenosis

scholarly journals In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario

2019 ◽  
Vol 71 (1) ◽  
Author(s):  
Ganesh Paramasivam ◽  
Tom Devasia ◽  
Shabeer Ubaid ◽  
Ashwitha Shetty ◽  
Krishnananda Nayak ◽  
...  
Keyword(s):  
Real World ◽  
Clinical Presentation ◽  
Drug Eluting Stents ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
In Stent Restenosis
Sign in / Sign up

Export Citation Format

Share Document